Viewing nowCombinationHabika HCT Tablets 5/40/12.5 Milligrams
Olmesartan Medoxomil 40mg · Amlodipine Besylate 6.944mg +1 more
Tablet · Prescription medication · Combination
White Life Science Co., Ltd.

MFDS item code 202002773 · Approved 2020.04.20 · Insurance code 625202010
Treatment of essential hypertension not controlled with concomitant amlodipine and olmesartan
The combination therapy of Amlodipine and Olmesartan Medoxomil is used to treat essential hypertension, which is hypertension of unknown origin. These medications effectively lower blood pressure through different mechanisms, helping to dilate blood vessels and increase sodium excretion by the kidneys for blood pressure control. It is particularly suitable for patients whose blood pressure is inadequately controlled by existing treatments and contributes to the prevention of cardiovascular complications. Taking this combination medication can help maintain stable blood pressure and improve health.
Take 1 tablet once daily with water, with or without food. If possible, it is recommended to take it at the same time each day (e.g., in the morning). Before starting this medicine, it is recommended that the dose of the individual components (olmesartan medoxomil and amlodipine, as monotherapy or combination therapy) be adjusted; however, direct switching to this medicine may be considered if blood pressure is not controlled with combination therapy of amlodipine and olmesartan medoxomil, as follows. The maximum dose of this medicine is 10/40/25 mg of amlodipine/olmesartan medoxomil/hydrochlorothiazide. The maximum antihypertensive effect occurs within 2 weeks of administration; therefore, adjust the dose at intervals of 2 weeks or more, taking the patient's blood pressure response into account. The recommended doses are as follows: - 5/20/12.5 mg: For patients whose blood pressure is not adequately controlled with combination therapy of amlodipine/olmesartan medoxomil 5/20 mg. - 5/40/12.5 mg: For patients whose blood pressure is not adequately controlled with combination therapy of amlodipine/olmesartan medoxomil 5/40 mg or this medicine 5/20/12.5 mg. - 5/40/25 mg: For patients whose blood pressure is not adequately controlled with this medicine 5/40/12.5 mg. - 10/40/12.5 mg: For patients whose blood pressure is not adequately controlled with combination therapy of amlodipine/olmesartan medoxomil 10/40 mg or this medicine 5/40/12.5 mg. - 10/40/25 mg: For patients whose blood pressure is not adequately controlled with this medicine 5/40/25 mg or this medicine 10/40/12.5 mg. ※ Refer to the following dose-escalation schedule (the amounts of each component are listed in the order of amlodipine/olmesartan medoxomil/hydrochlorothiazide). 5/20/0 mg → 5/20/12.5 mg ↓ 5/40/0 mg → 5/40/12.5 mg → 5/40/25 mg ↓ ↓ 10/40/0 mg → 10/40/12.5 mg → 10/40/25 mg Patients with renal impairment The maximum dose of this medicine in patients with mild or moderate renal impairment (creatinine clearance 30-60mL/min) is 20/5/12.5 milligrams once daily. Monitoring of potassium and creatinine levels is recommended in patients with moderate renal impairment. This medicine should not be administered to patients with severe renal impairment (creatinine clearance < 30mL/min). Patients with hepatic impairment Caution should be exercised when administering this medicine to patients with mild or moderate hepatic impairment. The maximum dose of this medicine in patients with moderate hepatic impairment is 5/20/12.5 milligrams once daily. Blood pressure and renal function should be monitored closely in patients with hepatic impairment. This medicine should not be administered to patients with severe hepatic impairment. Elderly patients (65 years or older) In general, start treatment at a low dose. When adjusting the dose, consider the patient's renal or cardiac function and comorbidities. Blood pressure should be monitored closely and more frequently in elderly patients. Experience with this medicine in elderly patients aged 75 years or older is very limited; therefore, monitor very carefully when administering this medicine.
Administration of this medicine is not recommended in pediatric patients younger than 18 years because its safety and efficacy have not been established.
This medication may cause severe harm to the fetus and newborn during the second and third trimesters of pregnancy, so it must be discontinued immediately upon confirmation of pregnancy. Do not use if you are allergic to this drug or its components, or if you have certain heart, kidney, or liver diseases. Patients with extremely low blood pressure or those in an unstable condition after acute myocardial infarction, as well as those with biliary obstruction or cholestatic liver disease, should not take this medication. Patients with low blood volume or salt deficiency may experience hypotension, so it is essential to assess their condition carefully before starting treatment and take appropriate measures if needed. Patients with weakened kidney function or those who have received kidney transplants should have regular kidney function tests while taking this medication, and it is best not to use it with severe kidney impairment. Patients with liver dysfunction or progressive liver disease need to exercise caution, and it is not recommended for those with severe liver impairment. This medication may cause dizziness due to its blood-pressure-lowering effect, so be cautious when driving or operating heavy machinery. Electrolyte levels in the blood should be monitored regularly while taking this medication, as changes in potassium, sodium, calcium, and other levels may occur. Particularly, elderly patients, as well as those with diabetes or gout, need to be more cautious. This medication may interact with other drugs, so inform your doctor or pharmacist if you are currently taking other medications. Breastfeeding women are advised not to take this medication, and if necessary, should either discontinue breastfeeding or the medication. Safety and efficacy have not been established for children under 18 years of age, so its use is not recommended. In case of overdose, severe hypotension and palpitations may occur, necessitating immediate medical attention. Store this medication away from direct sunlight and humidity, and keep it out of the reach of children.
Peripheral edema, headache, dizziness, upper respiratory infection, nasopharyngitis, urinary tract infection, sialadenitis, leukopenia, thrombocytopenia, bone marrow suppression, neutropenia, agranulocytosis, hemolytic anemia, aplastic anemia, anaphylactic reaction, drug hypersensitivity, hyperkalemia, hypokalemia, anorexia, diabetes, hypercalcemia, hyperglycemia, hypomagnesemia, hyponatremia, hypochloremia, hypertriglyceridemia, hypercholesterolemia, hyperuricemia, hypochloremic alkalosis, hyperamylasemia, confusional state, depression, apathy, sensitivity to stimulation, anxiety, mood changes, sleep disturbances, orthostatic dizziness, syncope, taste disturbance, hypertonia, sensory loss, paresthesia, peripheral neuropathy, drowsiness, fainting, seizures, loss of appetite, tremor, visual disturbances, reduced tear production, myopia worsening, jaundice, vertigo, tinnitus, palpitations, tachycardia, myocardial infarction, arrhythmia, angina, hypotension, flushing, orthostatic hypotension, vasculitis, thrombosis, embolism, cough, bronchitis, dyspnea, pharyngitis, rhinitis, acute interstitial pneumonia, respiratory distress syndrome, pulmonary edema, diarrhea, nausea, constipation, dry mouth, abdominal pain, change in bowel habits, abdominal distension, dyspepsia, gastritis, stomach discomfort, gastroenteritis, gingival hyperplasia, paralytic ileus, pancreatitis, vomiting, hepatitis, jaundice, acute cholecystitis, autoimmune hepatitis, hair loss, angioedema, allergic dermatitis, erythema multiforme, erythema, lupus erythematosus-like reaction of the skin, pustular rash, exfoliative dermatitis, sweating, phototoxic reaction, pruritus, purpura, Quincke's edema, rash, recurrence of lupus erythematosus of the skin, toxic skin necrosis, skin discoloration, Stevens-Johnson syndrome, urticaria, muscle cramps, joint swelling, muscle weakness, ankle swelling, arthralgia, arthritis, low back pain, paresis, myalgia, bone pain, polyuria, acute renal failure, hematuria, urination disorders, nocturia, interstitial nephritis, renal failure, erectile dysfunction, gynecomastia, asthenia, fatigue, chest pain, fever, influenza-like symptoms, lethargy, malaise, edema, pain, facial swelling, elevated serum creatinine, elevated blood urea, elevated serum uric acid, decreased serum potassium, elevated gamma-glutamyl transferase, elevated alanine aminotransferase, elevated aspartate aminotransferase, elevated liver enzymes, elevated serum creatinine phosphokinase, weight loss, weight gain, rhabdomyolysis, chronic malabsorption syndrome, intestinal angioedema, altered consciousness, drug hypersensitivity, epigastric pain, decreased libido, labial edema, apathy, loss of consciousness, eczema, limb pain, mild decrease in average hemoglobin and hematocrit levels, dizziness, benign prostatic hyperplasia, benign salivary gland neoplasm, cerebral infarction, renal failure, abdominal distension, facial flushing, nosebleed, prostatic hyperplasia, prostatitis, dysphagia, papular rash, renal cell dysplasia, acute hearing loss, lymphadenitis, acute respiratory distress syndrome
Not everyone experiences these, and they can vary from person to person.
This medication may be sensitive to air and moisture and should be stored in a tightly sealed container. The recommended storage temperature is room temperature, between 1 to 30 degrees Celsius. Proper storage will help maintain the medication's efficacy and safety over time.
Pale yellow round film-coated tablets
30 tablets (10 tablets/Alu-Alu x 3)
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowCombinationOlmesartan Medoxomil 40mg · Amlodipine Besylate 6.944mg +1 more
Tablet · Prescription medication · Combination
White Life Science Co., Ltd.
CombinationOlmesartan Medoxomil 40mg · Amlodipine Besylate 6.944mg +1 more
Tablet · Prescription medication · Combination
Hanmi Daiichi Sankyo Co., Ltd.
CombinationOlmesartan Medoxomil 40mg · Amlodipine Besylate 13.888mg +1 more
Tablet · Prescription medication · Combination
Daicel Corporation (Co., Ltd.)
CombinationOlmesartan Medoxomil 20mg · Amlodipine Besylate 6.944mg +1 more
Tablet · Prescription medication · Combination
HanKook Daiichi Sankyo Co., Ltd.
Olmesartan Medoxomil · Amlodipine Besylate +1 more
Prescription medication · Combination
SYNEX Co., Ltd.
Olmesartan Medoxomil · Amlodipine Besylate +1 more
Prescription medication · Combination
SYNEX Co., Ltd.
Olmesartan Medoxomil · Amlodipine Besylate +1 more
Prescription medication · Combination
SYNEX Co., Ltd.
CombinationAmlodipine Besylate 6.944mg · Olmesartan Medoxomil 20mg +1 more
Tablet · Prescription medication · Combination
JW Pharmaceutical Corporation
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.